|
Name |
Diepoxin kappa
|
| Molecular Formula | C21H18O8 | |
| IUPAC Name* |
(1'S,2'S,3'R,5'R,7'R,10'R,11'S)-2',11'-dihydroxy-10'-methoxyspiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,6'-4,12-dioxatetracyclo[5.4.1.01,7.03,5]dodecane]-8'-one
|
|
| SMILES |
CO[C@@H]1CC(=O)[C@@]23[C@@]([C@H]1O)(O2)[C@H]([C@@H]4[C@H](C35OC6=CC=CC7=C6C(=CC=C7)O5)O4)O
|
|
| InChI |
InChI=1S/C21H18O8/c1-25-12-8-13(22)20-19(29-20,16(12)23)17(24)15-18(26-15)21(20)27-10-6-2-4-9-5-3-7-11(28-21)14(9)10/h2-7,12,15-18,23-24H,8H2,1H3/t12-,15-,16+,17+,18-,19+,20+/m1/s1
|
|
| InChIKey |
WGCFPWGLKTUIGC-BTDHYDEWSA-N
|
|
| Synonyms |
Diepoxin kappa; CHEMBL3342628
|
|
| CAS | NA | |
| PubChem CID | 102223267 | |
| ChEMBL ID | CHEMBL3342628 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 398.4 | ALogp: | 0.0 |
| HBD: | 2 | HBA: | 8 |
| Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 110.0 | Aromatic Rings: | 7 |
| Heavy Atoms: | 29 | QED Weighted: | 0.676 |
| Caco-2 Permeability: | -5.34 | MDCK Permeability: | 0.00004470 |
| Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.996 |
| Human Intestinal Absorption (HIA): | 0.028 | 20% Bioavailability (F20%): | 0.038 |
| 30% Bioavailability (F30%): | 0.955 |
| Blood-Brain-Barrier Penetration (BBB): | 0.728 | Plasma Protein Binding (PPB): | 90.24% |
| Volume Distribution (VD): | 0.571 | Fu: | 2.38% |
| CYP1A2-inhibitor: | 0.075 | CYP1A2-substrate: | 0.859 |
| CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.667 |
| CYP2C9-inhibitor: | 0.033 | CYP2C9-substrate: | 0.024 |
| CYP2D6-inhibitor: | 0.005 | CYP2D6-substrate: | 0.177 |
| CYP3A4-inhibitor: | 0.075 | CYP3A4-substrate: | 0.58 |
| Clearance (CL): | 11.187 | Half-life (T1/2): | 0.62 |
| hERG Blockers: | 0.044 | Human Hepatotoxicity (H-HT): | 0.994 |
| Drug-inuced Liver Injury (DILI): | 0.983 | AMES Toxicity: | 0.964 |
| Rat Oral Acute Toxicity: | 0.737 | Maximum Recommended Daily Dose: | 0.116 |
| Skin Sensitization: | 0.914 | Carcinogencity: | 0.811 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.034 |
| Respiratory Toxicity: | 0.947 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002330 | ![]() |
0.831 | D08CCE | ![]() |
0.254 | ||
| ENC003239 | ![]() |
0.831 | D0Q3VE | ![]() |
0.237 | ||
| ENC001999 | ![]() |
0.695 | D00JRA | ![]() |
0.216 | ||
| ENC001988 | ![]() |
0.626 | D0AZ8C | ![]() |
0.215 | ||
| ENC002185 | ![]() |
0.610 | D06TJJ | ![]() |
0.211 | ||
| ENC003195 | ![]() |
0.604 | D01TNW | ![]() |
0.211 | ||
| ENC003194 | ![]() |
0.558 | D0A0JH | ![]() |
0.207 | ||
| ENC003197 | ![]() |
0.514 | D06ALD | ![]() |
0.204 | ||
| ENC003198 | ![]() |
0.505 | D09WKB | ![]() |
0.202 | ||
| ENC003196 | ![]() |
0.500 | D05MQK | ![]() |
0.201 | ||